- Home
- AGCO vs NUVL Comparison
AGCO vs NUVL Comparison
Compare AGCO & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGCO
- NUVL
- Stock Information
- Founded
- AGCO 1990
- NUVL 2017
- Country
- AGCO United States
- NUVL United States
- Employees
- AGCO N/A
- NUVL N/A
- Industry
- AGCO Industrial Machinery/Components
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- AGCO Industrials
- NUVL Health Care
- Exchange
- AGCO Nasdaq
- NUVL Nasdaq
- Market Cap
- AGCO 7.3B
- NUVL 6.7B
- IPO Year
- AGCO 1992
- NUVL 2021
- Fundamental
- Price
- AGCO $96.86
- NUVL $88.10
- Analyst Decision
- AGCO Buy
- NUVL Strong Buy
- Analyst Count
- AGCO 13
- NUVL 10
- Target Price
- AGCO $115.00
- NUVL $112.60
- AVG Volume (30 Days)
- AGCO 867.0K
- NUVL 350.8K
- Earning Date
- AGCO 02-04-2025
- NUVL 11-12-2024
- Dividend Yield
- AGCO 1.20%
- NUVL N/A
- EPS Growth
- AGCO N/A
- NUVL N/A
- EPS
- AGCO 2.26
- NUVL N/A
- Revenue
- AGCO $12,575,300,000.00
- NUVL N/A
- Revenue This Year
- AGCO N/A
- NUVL N/A
- Revenue Next Year
- AGCO N/A
- NUVL N/A
- P/E Ratio
- AGCO $42.90
- NUVL N/A
- Revenue Growth
- AGCO N/A
- NUVL N/A
- 52 Week Low
- AGCO $84.35
- NUVL $61.80
- 52 Week High
- AGCO $130.26
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- AGCO 48.47
- NUVL 37.85
- Support Level
- AGCO $95.24
- NUVL $84.64
- Resistance Level
- AGCO $98.31
- NUVL $96.42
- Average True Range (ATR)
- AGCO 2.50
- NUVL 2.94
- MACD
- AGCO -0.32
- NUVL -0.74
- Stochastic Oscillator
- AGCO 22.56
- NUVL 26.95
About AGCO AGCO Corporation
Agco is a global manufacturer of agricultural equipment. The company has five core brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements to grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes about 3,100 dealer and distribution locations. Agco offers retail and wholesale financing to customers through its joint venture with Rabobank, a European food- and agriculture-focused bank.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.